chevron_leftBack
As of 13 June 2026, VYNE Therapeutics Inc. has a market cap of $21.17M USD, ranking #36718 globally and #4970 in the United States.
It ranks #3298 in the Healthcare sector, and #1105 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$21.17MUSD
Enterprise Value
-$7.7MUSD
Revenue (TTM)
$570.0KUSD
EBITDA (TTM)
-$29.73MUSD
Net Income (TTM)
-$26.48MUSD
PS Ratio
37.4
PB Ratio
0.8
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
David Domzalski
open_in_new
Employees
10
Founded
2003
IPO
25 Jan 2018
Website
vynetherapeutics.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -0.7% | -1.5% | 6.7% | 12% | 79% | -56% |
News
Loading...
VYNE Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
VYNE
VYNE Therapeutics Inc
ISIN: US92941V3087
Shares Out.:
Shares Outstanding:
33.353M1
Shares Float:
31.402M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
0.6353 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About VYNE Therapeutics Inc.
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company’s lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. The company was founded in 2003 and is based in Stewartsville, New Jersey.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
4M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
3M%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
2M%
|
97.4
|
|
NYSE: MRK
|
$274.03B
1M%
|
15.1
|
|
NYSE: PFE
|
$149.38B
705K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
555K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
2M%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
1M%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
1M%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
859K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
520K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
512K%
80.96B GBP
|
14.6
|
chevron_leftBack